Aedes mosquitos and can result in severe congenital and adult neurologic abnormalities. ZIKV has rapidly spread northward through Central America and the Caribbean and autochthonous cases have been identified in the continental United States. High rates of ZIKA RNA positivity were detected in blood donors during previous epidemics. ZIKV transmission by transfused blood from healthy donor components has been a growing concern.
maculopapular rash, conjunctivitis, and arthralgias. [18] [19] [20] [21] As the virus spread throughout northeastern Brazil the temporal and regional associations between ZIKV outbreaks and severe congenital neurologic diseases became increasingly compelling. 2, 22, 23 Of greatest concern ZIKV infection of pregnant women has been unequivocally associated with congenital transmission and brain abnormalities including severe microcephaly, a rare newborn condition linked to fetal infections with other viruses, but not previously with arboviruses. [24] [25] [26] Based on studies from the South Pacific outbreaks it is estimated that less than 20% of infected persons experience symptoms and the acute viremia is thought to last only 1 to 2 weeks. During this period high levels of viremia may occur and viremia can reach levels exceeding 10 8 copies/mL in serum or plasma. Blood donor RNA positivity rates of 2.8% were documented in a blood donor screening study during the French Polynesia outbreak. 9 Well-documented cases of transfusion transmission were reported in Brazil in 2016 7, 8 linked to donations with archived samples that had high ZIKV RNA levels during the viremic phase of ZIKV infection, leading to growing concerns about the risk of transfusion transmission. 9, [27] [28] [29] With endemic transmission of ZIKV confirmed in over 38 countries or territories in the Americas, including Puerto Rico and numerous Caribbean islands and travelrelated cases diagnosed throughout the continental United States, the Food and Drug Administration (FDA) 30, 31 and AABB 32 issued guidance documents to reduce the risk of transfusion transmission of ZIKV in the continental United States. The first FDA guidance in February 2016 recommended that Puerto Rican blood donations be screened by investigational nucleic acid amplification technology (NAT) assays, treated with approved pathogen reduction technologies, or imported. 30 As a result, ZIKV NAT screening was rapidly implemented in April 2016 for Puerto Rico donations. Infected blood donors were immediately identified with increasing NAT yield rates through the summer of 2016. 33 Confirmation of ZIKV RNA in asymptomatic donors in Puerto Rico, which reached rates of 1.8% of donations at the peak of the outbreak, 30% of which were negative by simulated minipool testing, as well as increasing numbers of travel acquired cases in the continental United States, led the FDA to issue a revised guidance in August 2016. 31 
MATERIALS AND METHODS
Blood donor screening for ZIKV became available through the Hologic, Inc., investigational new drug (IND) protocol on June 20, 2016. Creative Testing Solutions (CTS) laboratories in Tempe, Arizona, and Bedford, Texas, began performing the Procleix ZIKV assay in late July for blood centers in the defined 11-state area, with full implementation of universal ID-NAT screening for Zika for all client blood centers before September 23. Plasma (0.5 mL) from volunteer blood donors was tested individually with the investigational Procleix ZIKV assay on the Procleix Panther system in accordance with the package insert instructions.
Individual-donor plasma samples with initially reactive ZIKV NAT results were retested in duplicate and submitted for supplemental ZIKV testing. Every effort was made to contact and consent reactive donors to return for follow-up visits at the blood collection facilities. The first follow-up visits were scheduled as soon as possible after the index donation, preferably within 7 days of the donation date that yielded the initial reactive result. Thereafter, collection centers followed reactive donors approximately every week. If the supplemental testing indicated probable ZIKV infection the donors were followed until they had a follow-up sample result that was Procleix ZIKV NAT nonreactive on plasma and serologically reactive (Zikaspecific antibody seroconversion).
Supplemental ZIKA testing and interpretation
If an individual donor sample was nonreactive, then no further testing was performed. Available plasma aliquots from ZIKV NAT-reactive index donations were refrigerated once testing completed and then separated into plasma, serum, and red blood cell (RBC) aliquots. Aliquots were frozen and stored at less than 2708C until shipped on dry ice to Blood Systems Research Institute (BSRI; San Francisco, CA) for confirmation and viral load (VL) determination using a ZIKV reverse transcription-polymerase chain reaction (RT-PCR) assay based on the Centers for Disease Control and Prevention (CDC) PCR assay that has received FDA Emergency Use Authorization but with enhanced input of eluate to increase sensitivity. 34, 35 were performed as directed in the manufacturer's instructions, using the suggested P/N cutoffs for the IgM assay of 4.47 and 5.66 for equivocal and positive, respectively. Furthermore, ZIKV and DENV neutralization tests were performed on follow-up samples from IgM positive individuals using reporter virus particles (RVP; Integral Molecular). These assays involve parallel titration of donor serum on RVPs bearing the structural proteins of ZIKV and the four DENVs, as previously described. 40, 41 A confirmed positive classification required that the donor tested NAT reactive on the index donation plasma with confirmation of RNA by alternate or primary NAT on plasma or RBCs from the index donation and/or follow-up samples and with confirmation of ZIKV antibodies by IgM corroborated with RVP neutralization. Presumed falsepositive donors were defined as ZIKV initial NAT-reactive cases with index and (when available) follow-up samples that tested negative by both Procleix ZIKV and supplemental ZIKV RNA and serology assays.
Ethical approval
Routine informed consent for blood donation was obtained at the time of donation, including authorization for testing for other transfusion-transmitted infectious diseases, as required of all blood donors. The routine consent includes information related to the potential use of donation-derived samples and demographic information for research purposes. An IND study-specific information sheet related to Zika testing and participation in the clinical trial was also provided to every donor before donation. If the donor tested ZIKV NAT reactive an additional informed consent was provided that gave permission for follow-up sample acquisition and testing. All study procedures and consent documents were approved by the Chesapeake Institutional Review Board.
RESULTS
Between September 19 and November 30, 2016, a total of 466,834 donations were screened for ZIKV RNA at CTS laboratories in Tempe, Arizona, and Bedford, Texas, using the investigational Procleix ZIKV assay. Twenty donations ( Tables 1 and 2 . Four of these donations were collected in areas considered to not have active autochthonous transmission of ZIKV (Nevada, New York, Arizona, and California) and one was collected in Texas, an area only recognized in late November as having potential local transmission. 17 Donor 1 (Nevada) Donor 1 provided a blood donation on September 26, 2016, in Nevada. The investigational Procleix ZIKV assay was initially reactive but the sample was negative when retesting in duplicate by the screening NAT assay. Upon subsequent testing at BSRI, index donation plasma from Donor 1 was negative by an alternate NAT assay (RT-PCR), but serum was strongly positive for Zika IgM (P/N of 7.2) and IgG (P/N of 4.0) capture ELISAs and for anti-ZIKVspecific neutralizing antibodies by RVP neutralization testing. Serum from the index donation from Donor 1 was negative for DENV IgM but weakly reactive for DENV IgG by ELISA (P/N of 1.9), likely due to weak cross-reactivity with high-titer ZIKV IgG; little neutralizing activity against the four DENVs was detected by RVP testing, even at a dilution of only 1 in 10 ( Fig. 2 and Table 2 ).
The donor consented to enrollment into the followup study. An interview revealed a travel history to Managua and Diriamba, Nicaragua, between May 2 and August 16, 2016. Furthermore, the donor reported developing symptoms consistent with ZIKV infection during the week of August 7 to 14, 2016, before returning to the United States. The whole blood donation that tested ZIKV positive was donated 41 days after return to the United States and 50 days subsequent to the onset of symptoms indicative of probable recent acquisition of ZIKV infection.
Because Donor 1's index donation plasma tube tested initially reactive but not repeat reactive by the Procleix ZIKV assay and was negative by the supplemental PCR assays performed, the plasma component was retrieved and 25 additional 0.5-mL aliquots were tested by the Procleix ZIKV assay at CTS and Hologic, which yielded two of 25 reactive results. RBCs from both the EDTA tubes and the leukoreduced RBC (LR-RBC) component were tested at BSRI by the alternate NAT (RT-PCR) assay, which demonstrated moderate levels of ZIKV RNA (Table 1) . RBC samples were also prepared using Hologic's parasite transport medium (PTM) 42 developed for whole blood sample preparation for Babesia testing followed by replicate dilutional testing with the Procleix ZIKV assay on the Panther system at Hologic's R&D laboratory in San Diego, California; ZIKV RNA was reproducibly detected (10/10 replicates/dilution) in RBC specimens down to a 1:300 dilution. Donor 1 completed three follow-up visits over the month after the index donation. The subsequent three samples were all nonreactive for ZIKV RNA in plasma with the investigational Procleix ZIKV assay and supplemental PCR test, but demonstrated moderate levels of ZIKV RNA associated with RBC samples detected both by the investigational Procleix ZIKV assay and supplemental PCR test. As seen in Tables 1 and 2 , and in Fig. 2A , the serial index and follow-up samples indicated continued evolution of viral and serologic markers, with declining RBC VL, declining anti-ZIKV IgM reactivity, and increasing anti-ZIKV IgG and RVP neutralization reactivity.
Donor 2 (New York)
Donor 2 provided a blood donation on September 26, 2016, in New York that initially tested reactive by the investigational Procleix ZIKV assay but negative when retested in duplicate. Upon subsequent testing at BSRI, plasma from Donor 2's index donation was reactive on one of two replicates of the alternate NAT assay (RT-PCR cycle threshold [Ct] 38.5; below the limit of quantitation), and serum was reactive for ZIKV IgM (P/N of 6.5) and IgG (P/N of 3.1). Donor 2 was negative for DENV IgM but weakly reactive for DENV IgG (P/N of 2.0). RVP neutralization testing indicated that the antibody reactivity was ZIKV specific with greater than fourfold stronger neutralization of the ZIKV RVPs compared to any of the four DENV RVPs. RBCs from the index donation EDTA tubes tested positive for ZIKV RNA by supplemental PCR ( Table 1) . As this was an apheresis PLT donation a frozen plasma component was not available to allow for further replicate testing for ZIKV RNA. Donor 2 consented to enrollment into the follow-up study and completed three follow-up visits over a 6-week period after the index donation. An interview revealed a travel history to Trinidad beginning June 8 and returning June 21, 2016, which was 97 days before the ZIKV-positive donation date. No symptoms consistent with ZIKV infection were reported during or subsequent to the travel exposure. The subsequent three samples were all nonreactive with the investigational Procleix ZIKV assay and supplemental PCR and demonstrated a similar pattern of reactivity on the supplemental serologic testing as well as testing positive for ZIKV RNA on RBC samples (Table 2 ; * Serum dilution required to achieve 80% reduction in titer. † For DENV all four serotypes were tested, but only the most sensitive to neutralization is reported and used for the ratio. The specific serotype is denoted in parentheses. Equ 5 equivocal; Neg 5 negative; NT 5 not tested; P/N 5 positive to negative ratio; Pos 5 positive.
immunofluorescence assay (indicating absence of flavivirus antibodies). These results suggest that Zika infection did not occur after transfusion of a PLT component with probable low levels of ZIKV RNA in plasma and moderate levels of ZIKV RNA associated with RBCs.
Donor 3 (Arizona)
Donor 3 provided a blood donation on October 14, 2016, in Arizona. The investigational Procleix ZIKV assay was initially reactive, and one of two repeat tests was also reactive (Table 1) . Upon subsequent testing at BSRI, Donor 3 was negative by alternate NAT (RT-PCR) on plasma but strongly positive on RBCs from the EDTA tube and the LR-RBC component (Table 1) . Donor 3 was strongly reactive for ZIKV IgM (P/N of 17.2) and IgG (P/N of 7.0), negative for DENV IgM, and weakly reactive for DENV IgG (P/N of 1.5; Table 2 ). RVP neutralization testing indicated that the antibody reactivity was Zika specific. Replicate testing of 36 plasma aliquots from the frozen plasma component demonstrated low level reactivity (6/36) on the investigational Procleix ZIKV assay. Donor 3 did not enroll into the follow-up study, but reported a history of travel to Mexico City and various cities in the state of Oaxaca, Mexico, between August 17 and 24, 2016, returning to Arizona 52 days before the date of the ZIKV NAT-reactive donation. He reported fever and a rash beginning September 25, 2016, but no sexual contact or other travel exposure between returning to the United States on August 27, 2016, and onset of these symptoms.
Donor 4 (California)
Donor 4 provided a blood donation on October 27, 2016, in California. The investigational Procleix ZIKV assay was initially reactive, but both repeat tests were nonreactive ( Table 1 ). The index donation plasma sample from the EDTA tube was negative on both replicates of the alternate NAT assay, and none of 20 replicate investigational Procleix ZIKV assays performed on plasma derived from the plasma component was reactive. RBCs from both the index donation EDTA tubes and the LR-RBC component had moderate levels of ZIKV RNA by the alternate NAT (Table 1) and ZIKV RNA was detected in 10 of 10 replicate investigational Procleix ZIKV assays performed on RBCs lysed using PTM at Hologic. Donor 4 enrolled into the follow-up study and provided a follow-up sample on November 3, 2016. The donor had traveled to Mexico (Puerto Vallarta) between September 17 and September 23, 2016. He acknowledged three mosquito bites and a 3-day history of rash on arms and legs near the end of the trip to Mexico. RBCs from the index donation and follow-up samples were tested in parallel and were positive for ZIKV RNA (Table 1) . Anti-ZIKV IgM declined on the follow-up serum (P/N 12.5) sample relative to the level of reactivity on the index serum sample (P/N 15.4), suggesting waning of IgM consistent with acquisition of infection several months before the index donation. ZIKV IgG was reactive at index (P/N 3.1) and there was weak DENV IgG ELISA cross-reactivity (P/N 1.3). Parallel RVP neutralization testing of index donation and follow-up serum samples demonstrated strong inhibition of ZIKV infectivity, in comparison to very weak DENV 3 neutralization (Table 2) . reactive by investigational Procleix ZIKV assay but both repeat NATs were nonreactive using plasma from the same EDTA tube that yielded the positive result. The index plasma sample was borderline reactive for ZIKV RNA on both replicate alternate NAT assays performed at BSRI on EDTA tube-derived plasma (Ct 39.8, below limit of quantitation). The plasma component was retrieved and 10 replicates of the Procleix ZIKV NAT performed at CTS were all nonreactive, as were five replicates of a simulated minipool (1:16) of this plasma. Hologic also performed 20 replicate Procleix ZIKV assays on component-derived plasma with one reactive result. RBCs from the EDTA tube were positive for ZIKV RNA (Table 1) and ZIKV RNA was detected in 10 of 10 Procleix ZIKV assay replicates performed on the index donation RBCs lysed using PTM at Hologic. Index donation serum was strongly reactive for ZIKV IgM and IgG (Table 2) . Donor 5 enrolled in the follow-up study and provided a follow-up sample on November 18, 2016. The donor reported that he travels most weekends across the border to Matamoros, Mexico, and that he had experienced several days of symptoms consistent with ZIKV disease beginning October 28, 2016. The follow-up sample was negative for ZIKV RNA in plasma by both Hologic TMA and alternate NAT assays, but was still positive for RBCassociated RNA but with a lower VL than index ( Table 1) . The index and follow-up samples were tested in the same serology runs and both samples had strong ZIKV IgM and IgG reactivity, with declining ZIKV IgM reactivity but increasing IgG reactivity (Table 2) . While strong anti-ZIKV neutralization was observed, increasing DENV neutralization was also seen (80% neutralization titer [NT 80 ] at index of 364, <10, 87, and 894 for DENV1-4, respectively). This suggests prior exposure to DENV, most likely at least to DENV4.
The Texas Department of State Health Services is now recommending Zika testing of all pregnant women living in Brownsville, Texas, or who have traveled to Brownsville on or after October 29 due to recent local activity. 17 It is possible Donor 5 could have acquired infection locally in Brownsville, Texas, and may be an autochthonous case, rather than a travel-acquired case.
Assay specificity
The absence of a gold standard with which to compare investigational assays can make determination of an appropriate denominator for calculation of sensitivity and specificity of new assays problematic. For this calculation, donations were assumed to be without ZIKV infection if they were nonreactive on the initial screen with Procleix ZIKV assay or were initially reactive on Procleix ZIKV assay but did not demonstrate any further results which were indicative of probable ZIKV infection (i.e., the 15 cases classified as false positives [ Fig. 1]) . 
DISCUSSION
The potential for ZIKV transmission by transfused blood components has been a growing concern due to the recent detection of ZIKV RNA in healthy blood donors and cases of probable transfusion-transmitted ZIKV in Brazil. 7, 8 At least three donors developed symptoms consistent with ZIKV infection during or shortly after returning from travel to ZIKV risk countries (one had fever, rash, headache, arthralgia and myalgia; another had fever, headache and conjunctivitis; a third only had a rash, with a fourth donor reporting fever and rash 32 days after travel exposure ended). All five cases exhibited low ZIKV RNA levels in index donation plasma, based on the stochastic replicate investigational Procleix NAT and PCR testing of EDTA tube plasma and on plasma derived from retrieved frozen plasma components in three cases. In contrast, moderate levels (36-940 IU/mL) of ZIKV RNA were consistently detected associated with RBCs from index donation and follow-up EDTA pilot tubes, and in two cases from LR-RBC components derived from the index donations (Table 1) . Additionally, we observed robust ZIKV IgM reactivity that trended downward over time, and increasing ZIKV IgG and neutralizing antibody activity based on serial sample testing in all four donors that enrolled into the follow-up study.
These donors most likely represent "tail-end infections" with prolonged RBC-associated ZIKV RNA detected by the initial donor screening NAT assay performed on plasma. We observed stochastic detection of RNA on replicate testing on fresh-frozen plasma components from two of three cases, and undetectable RNA in plasma on follow-up for four cases, in contrast to moderate levels of RBC-associated ZIKV RNA in the presence of rising levels of ZIKV IgG and RVP reactivity. These data are consistent with the patterns we would anticipate, are consistent with a small case series for ZIKV infected travelers, 43, 44 and are similar to what has been documented in follow-up studies of WNV-infected donors. 45 Although these donors were likely infected several months before the index donations, they continued to demonstrate declining trends in levels of ZIKV IgM reactivity and increasing ZIKV IgG reactivity by ELISAand ZIKV-specific neutralizing activity by RVP testing. These insights into ongoing seroconversion profiles several months after ZIKV infection provide hope that serologic assays can be developed to discriminate recent from remote ZIKV infection; this is an important assay development goal given that in many epidemic regions a substantial proportion of the population will have ZIKV antibodies from prior season infections, yet pregnant women will require monitoring for recent acquisitions that could result in congenital transmission and disease.
It will be important to determine if transfusions of RBCs from these kinds of tail-end infections are infectious. However, the lack of transmission to the recipient of an apheresis PLT collected 7 days before the ZIKV RNApositive donation from Donor 2, 90 days after returning from Trinidad, the likely source of the exposure, suggests that these units may not be infectious. Since the tail-end cases are characterized by ZIKV RNA in the RBC fraction, and since apheresis PLTs contain few (if any) RBCs, the negative lookback result may not be generalizable to transfusions from such donors. However, additional studies are in progress to evaluate the infectivity of ZIKV RNApositive RBCs from time points after plasma RNA is no longer detectable, including inoculations into cell lines and murine and macaque models that are susceptible to ZIKV infection.
